Effect of statins on platelet function in patients with hyperlipidemia

Joanna Sikora, Barbara Kostka, Iwona Marczyk, Urszula Krajewska, Maciej Chałubiński, Marlena Broncel, Joanna Sikora, Barbara Kostka, Iwona Marczyk, Urszula Krajewska, Maciej Chałubiński, Marlena Broncel

Abstract

Introduction: It is generally assumed that cholesterol reduction by statins is the predominant therapeutic result underlying their beneficial effects in cardiovascular disease. However, the action of statins may be partially independent of their effects on plasma cholesterol levels, as they combine lipid lowering with positive effects on hemorheological conditions and endothelial function. We evaluated the impact of statin treatment on platelet adhesion to fibrinogen (spontaneous and ADP-activated), along with ADP, collagen or ristocetin-induced aggregation in type II hyperlipidemic patients.

Material and methods: The study group included 70 persons: 50 patients affected by type II hyperlipidemia without concomitant diseases and 20 healthy volunteers. The effects of 8-week statin treatment (atorvastatin 10 mg/day, simvastatin 20 mg/day, or pravastatin 20 mg/day) on platelet activation were evaluated.

Results: Regardless of the type of statin, a significant decrease in ADP-induced platelet aggregation was observed: for atorvastatin 50.6 ±12.8% vs. 41.1 ±15.8% (p < 0.05), for simvastatin 57.2 ±18.0% vs. 44.7 ±22.1% (p = 0.05), and for pravastatin 55.8 ±19.5% vs. 38.8 ±23.3% (p < 0.05). There was no significant effect of statins on collagen or ristocetin-induced platelet aggregation and adhesion.

Conclusions: Therapy with statins beneficially modifies ADP-induced platelet aggregation in patients with hyperlipidemia and does not affect spontaneous or ADP-induced platelet adhesion to fibrinogen and platelet aggregation induced by collagen or ristocetin.

Keywords: hyperlipidemia; platelet adhesion; platelet aggregation; statins.

References

    1. Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561–71.
    1. Hartwich J, Dembińska-Kieć, Gruca A, et al. Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids. Platelets. 2002;13:141–51.
    1. Cha YJ, Chang EA, Kim C. Effects of endothelial cells and mononuclear leukocytes on platelet aggregation. Haematologia. 2000;30:97–106.
    1. Gaddam V, Li DY, Metha JL. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Therapeut. 2002;7:247–53.
    1. van Willigen G, Gorter G, Akkerman JW. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb. 1994;14:41–6.
    1. Hackeng CM, Huigsloot M, Pladet MW, Nieuwenhuis HK, van Rijn HJM, Akkerman JWN. Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling. Arterioscler Thromb Vasc Biol. 1999;19:239–47.
    1. Vlasova II. The effect of oxidatively modified low-density lipoproteins on platelet aggregability and membrane fluidity. Platelets. 2000;11:406–14.
    1. Chalubinski M, Broncel M. The influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in the treatment of auto-immune disorders. Med Sci Monit. 2010;16:11.
    1. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Atheroscler Thromb Vasc Biol. 2001;21:1712–9.
    1. Maurer-Spurej E, Pfeiler G, Maurer N, Lindner H, Glatter O, Devine DV. Room temperature activates human blood platelets. Lab Invest. 2001;8:581–92.
    1. Walkowiak B, Michalak E, Koziołkiewicz W, Cierniewski CS. Rapid photometric method for estimation of platelet count in blood plasma in platelet suspension. Thromb Res. 1989;56:763–6.
    1. Born GV. Aggregation of blood platelets by adenosine and reversal. Nature. 1962;195:927–9.
    1. Kostka B, Pająk W. The aggregometer equipment for recording of transmittance (T) with the possibility of scale extension. Diagn Lab. 1985;21:43–7.
    1. Kostka B, Sikora J, Para J, Krajewska U, Korzycka L. A new nitrate derivative of piperazine: its influence on platelet activity. Blood Coagul Fibrinol. 2007;18:151–6.
    1. Sikora J, Krajewska U, Gietka M, Kostka B. The application of pig blood in the in vitro measurement of platelet adhesion. Pharmazie. 2001;56:187–8.
    1. Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in plates. Anal Biochem. 1994;216:444–50.
    1. Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haemat. 1957;17:237.
    1. Balk EM, Lau J, Gaudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003;139:670–82.
    1. Veselka J, Hájek P, Malý, et al. Predictors of coronary intervention-related myocardial infarction in stable angina patients pre-treated with statins. Arch Med Sci. 2011;7:67–72.
    1. Xu M, Yuan G, Wei F. Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials. Arch Med Sci. 2010;6:866–73.
    1. Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916–22.
    1. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:121–6.
    1. Piotrowski M, Fisher S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose Atorvastatin compared with higher-dose Atorvastatin alone. J Am Coll Cardiol. 2007;49:1035–42.
    1. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyper-activity after statin treatment discontinuation. Thromb Haemost. 2003;90:476–82.
    1. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin. 2008;24:3059–62.
    1. Jagroop IA, Persaud JW, Mikhailidis DP. A new rapid method to measure human platelet cholesterol: a pilot dtudy. Clin Appl Thromb Hemost. 2011;17:578–84.
    1. Puccetti L, Pasqui AL, Pastorelli M, et al. Time-dependent effect of statins on platelet function in hypercholestero-laemia. Eur J Clin Invest. 2002;32:901–8.
    1. Bolaman Z, Kadikoylu G, Ozgel N, Yenisey C. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. J Natl Med Assoc. 2006;98:1273–7.
    1. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia: a pilot study involving serial sampling. Curr Med Res Opin. 2001;16:269–75.
    1. Bonnefoy A, Liu Q, Legrand, Frojmovic MM. Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow. Biophysical J. 2000;78:2834–43.
    1. Ozaki Y. Measurement of platelet aggregation and attempts for standardization. Sysmex J Inter. 1998;8:15–22.
    1. Hussain O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol. 2008;65:637–45.
    1. Dujove CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85:350–3.
    1. Dai K, Bodnar R, Berndt MC, Du X. A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood. 2005;106:1975–81.
    1. Szapary L, Horvayh B, Marton Z, et al. Short-term effects of low-dose Atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs. 2004;18:165–72.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다